Biorestorative Therapies, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
BioRestorative Therapies' VP of R&D, Francisco Silva, acquired common stock and warrants, increasing his beneficial ownership.
NASDAQ
BioRestorative Therapies' President, CEO, and COB, Lance Alstodt, acquired 15,625 common shares and 11,719 warrants.
NASDAQ
David A. Rosa, a director of BioRestorative Therapies, Inc., reports the acquisition of stock options exercisable for 52,632 shares of common stock.
NASDAQ
Patrick F. Williams, a director at BioRestorative Therapies, Inc., acquired stock options for 52,632 shares of common stock on February 14, 2025.
NASDAQ
Director Nickolay V. Kukekov reports acquisition of stock options in BioRestorative Therapies, Inc.
NASDAQ
Robert Eugene Kristal, CFO of BioRestorative Therapies, Inc., reports acquisition of stock options.
NASDAQ
Form 4: BioRestorative Therapies VP of Research and Development Reports Changes in Beneficial Ownership
Francisco Silva, VP of Research and Development at BioRestorative Therapies, reports changes in beneficial ownership, including the acquisition of stock options.
NASDAQ
Lance Alstodt, CEO of BioRestorative Therapies, reports the acquisition of stock options.
NASDAQ
Director Dale Broadrick sold 1,112 shares of BioRestorative Therapies, Inc. on October 28, 2024, at a price of $1.58 per share.
NASDAQ
Francisco Silva, VP of Research and Development at BioRestorative Therapies, Inc., reports purchasing common stock in multiple transactions.
NASDAQ
Francisco Silva, VP of Research and Development at BioRestorative Therapies, reports a transaction involving common stock and stock options.
NASDAQ
Lance Alstodt, CEO of BioRestorative Therapies, reports a transaction involving the withholding of shares to cover withholding taxes, resulting in an adjusted beneficial ownership.